Re-imagining cancer treatment, today
Therapeutics to reverse cancer drug resistance
and immune suppression.
Making A Difference
Kairos Pharma is a clinical-stage biopharmaceutical company that has developed novel therapies to overcome resistance to cancer drugs and reverse cancer-induced immune suppression.
The word “Kairos” means “the opportune moment to intervene.” Our therapies are designed to act at that critical point—when cancer drug resistance or immune suppression threatens a patient’s treatment.
Reversing Cancer Drug Resistance
Therapeutics for oncology often work for some time until inevitably resistance to the drug develops. The cancer then comes back often in a much more aggressive manner. Scientists at Kairos Pharma have discovered a central mechanism responsible for the development of cancer drug resistance. As patients are treated with Xtandi, Zytiga, or Erleada or other anti-androgen drugs for prostate cancer or with Tagrisso, Tarceva, or Iressa for lung cancer, the cancer starts making a protein called CD105 on the cancer cell surface which makes the cancer resistant to those drugs.
- Our drug ENV105 is an antibody that reverses the effect of CD105, rendering the cancer responsive to those drugs again.
- ENV105 is currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer.
- We are also planning clinical trials in several other cancer types with head and neck cancer next in line
As the CD105 mechanism appears to drive many forms of cancer drug resistance, ENV105 has the potential to address resistance in a wide range of cancers as they become resistant to standard treatments.
Reversing Immune Suppression
Cancer cells eventually secrete proteins that shut down T cells which attack the cancer cells. This state of immunosuppression worsens as the cancer grows. Kairos Pharma has developed technologies that reverse immune suppression to effectively mount a strong T cell response against the cancer.
We are committed to patients, caregivers, and the science of extending lives. Our focus is on developing novel therapies to overcome cancer drug resistance and reverse cancer-induced immune suppression to help ensure a patients journey to recovery can continue without interruption.
Central mechanism of cancer drug resistance and novel mechanisms to modulate immune response discovered by Kairos.
Innovative resistance and immunotherapy drugs with IP protection until 2040.
Strategic relationships with major medical centers.
Currently in Phase 2 trial in prostate cancer, Phase 1 trial in lung cancer and cleared IND in glioblastoma.
Join Us On Our Mission
We are a dynamic company driving innovation at the forefront of cancer research. Our therapies are set to revolutionize cancer drug interactions and help extend the lives of our patients.
Re-imagining cancer treatment, today
Therapeutics to reverse cancer drug resistance
and immune suppression.
Making A Difference
Kairos Pharma is a clinical-stage biopharmaceutical company that has developed novel therapies to overcome resistance to cancer drugs and reverse cancer-induced immune suppression.
The word “Kairos” means “the opportune moment to intervene.” Our therapies are designed to act at that critical point—when cancer drug resistance or immune suppression threatens a patient’s treatment.
Reversing Cancer Drug Resistance
Therapeutics for oncology often work for some time until inevitably resistance to the drug develops. The cancer then comes back often in a much more aggressive manner. Scientists at Kairos Pharma have discovered a central mechanism responsible for the development of cancer drug resistance. As patients are treated with Xtandi, Zytiga, or Erleada or other anti-androgen drugs for prostate cancer or with Tagrisso, Tarceva, or Iressa for lung cancer, the cancer starts making a protein called CD105 on the cancer cell surface which makes the cancer resistant to those drugs.
- Our drug ENV105 is an antibody that reverses the effect of CD105, rendering the cancer responsive to those drugs again.
- ENV105 is currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer.
- We are also planning clinical trials in several other cancer types with head and neck cancer next in line
As the CD105 mechanism appears to drive many forms of cancer drug resistance, ENV105 has the potential to address resistance in a wide range of cancers as they become resistant to standard treatments.
Reversing Immune Suppression
Cancer cells eventually secrete proteins that shut down T cells which attack the cancer cells. This state of immunosuppression worsens as the cancer grows. Kairos Pharma has developed technologies that reverse immune suppression to effectively mount a strong T cell response against the cancer.
We are committed to patients, caregivers, and the science of extending lives. Our focus is on developing novel therapies to overcome cancer drug resistance and reverse cancer-induced immune suppression to help ensure a patients journey to recovery can continue without interruption.
Central mechanism of cancer drug resistance and novel mechanisms to modulate immune response discovered by Kairos.
Innovative resistance and immunotherapy drugs with IP protection until 2040.
Strategic relationships with major medical centers.
Currently in Phase 2 trial in prostate cancer, Phase 1 trial in lung cancer and cleared IND in glioblastoma.
Join Us On Our Mission
We are a dynamic company driving innovation at the forefront of cancer research. Our therapies are set to revolutionize cancer drug interactions and help extend the lives of our patients.
Re-imagining cancer treatment, today
Therapeutics to reverse cancer drug resistance and immune suppression.
Making A Difference
Kairos Pharma is a clinical-stage biopharmaceutical company that has developed novel therapies to overcome resistance to cancer drugs and reverse cancer-induced immune suppression.
The word “Kairos” means “the opportune moment to intervene.” Our therapies are designed to act at that critical point—when cancer drug resistance or immune suppression threatens a patient’s treatment.
Reversing Cancer Drug Resistance
Therapeutics for oncology often work for some time until inevitably resistance to the drug develops. The cancer then comes back often in a much more aggressive manner. Scientists at Kairos Pharma have discovered a central mechanism responsible for the development of cancer drug resistance. As patients are treated with Xtandi, Zytiga, or Erleada or other anti-androgen drugs for prostate cancer or with Tagrisso, Tarceva, or Iressa for lung cancer, the cancer starts making a protein called CD105 on the cancer cell surface which makes the cancer resistant to those drugs.
- Our drug ENV105 is an antibody that reverses the effect of CD105, rendering the cancer responsive to those drugs again.
- ENV105 is currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer.
- We are also planning clinical trials in several other cancer types with head and neck cancer next in line
As the CD105 mechanism appears to drive many forms of cancer drug resistance, ENV105 has the potential to address resistance in a wide range of cancers as they become resistant to standard treatments.
Reversing Immune Suppression
Cancer cells eventually secrete proteins that shut down T cells which attack the cancer cells. This state of immunosuppression worsens as the cancer grows. Kairos Pharma has developed technologies that reverse immune suppression to effectively mount a strong T cell response against the cancer.
KROS101 is a novel small molecule that is the only known immunotherapy capable of both expanding T cell numbers and making them more effective at killing cancer cells.
KROS201 is a novel T cell therapy that targets and kills cancer stem cells which are believed to be the root cause of glioblastoma. KROS201 has cleared an Investigational New Drug (IND) application with the FDA to begin clinical trials.
We are committed to patients, caregivers, and the science of extending lives. Our focus is on developing novel therapies to overcome cancer drug resistance and reverse cancer-induced immune suppression to help ensure a patients journey to recovery can continue without interruption.
Central mechanism of cancer drug resistance and novel mechanisms to modulate immune response discovered by Kairos.
Innovative resistance and immunotherapy drugs with IP protection until 2040.
Strategic relationships with major medical centers.
Currently in Phase 2 trial in prostate cancer, Phase 1 trial in lung cancer and cleared IND in glioblastoma.
Join Us On Our Mission
We are a dynamic company driving innovation at the forefront of cancer research. Our therapies are set to revolutionize cancer drug interactions and help extend the lives of our patients.
